RecruitingNCT06738771

Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

Antimicrobial Therapy for Infections Due to Pseudomonas Aeruginosa With Difficult-to-treat Resistance: a Real-world, Prospective, Multicenter Cohort Study

Sponsor

Centre Hospitalier Régional d'Orléans

Enrollment

600 participants

Start Date

Mar 11, 2025

Study Type

OBSERVATIONAL

Conditions

Pseudomonas aeruginosa Prognosis Pseudomonas Infections Drug Resistance, Multiple, Bacterial Antibacterial Agents Beta-lactam Antibiotics

Summary

The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with antibacterial agents, beta-lactam antibiotics, and other related conditions. The study is currently recruiting participants at 48 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(48)

CHU Amiens

Amiens, France

CH Argenteuil

Argenteuil, France

CH Bayonne

Bayonne, France

CHU de BESANCON

Besançon, France

CH Bethune

Béthune, France

CHU Avicenne

Bobigny, France

CH Bourgoin-Jallieu

Bourgoin, France

CH Métropole Savoie

Chambéry, France

Ch de Chartres

Chartres, France

CHU Clermont Ferrand

Clermont-Ferrand, France

CHI Créteil

Créteil, France

CHU Henri Mondor

Créteil, France

CHI Elbeuf Louviers

Elbeuf, France

CH Sud Essone

Étampes, France

Hopital Raymond Poincaré

Garches, France

CHU Grenoble

Grenoble, France

CH Haguenau

Haguenau, France

CHD Vendée

La Roche-sur-Yon, France

Hopital Bicetre

Le Kremlin-Bicêtre, France

CHU Limoges

Limoges, France

CHU Lyon Sud

Lyon, France

CHU Lyon

Lyon, France

CHY Lyon

Lyon, France

Hopital Saint-Joseph Saint Luc

Lyon, France

CHU Montpellier

Montpellier, France

CHRU Nancy

Nancy, France

Chu de Nantes

Nantes, France

CHU de Nice

Nice, France

Centre Hospitalier Universitaire d'Orléans

Orléans, France

Hopital Bichat

Paris, France

Hopital Cochin

Paris, France

Hopital LARIBOISIERE

Paris, France

Hopital Pitie Salpetriere

Paris, France

Hopital Saint-Antoine

Paris, France

Hôpital Européen Georges Pompidou

Paris, France

Hôpital Saint-Louis

Paris, France

CH PAU

Pau, France

CH Perpignan

Perpignan, France

Centre Hospitalier de Périgueux

Périgueux, France

CHU Reims

Reims, France

CH Saint-Lô

Saint-Lô, France

CHRU Strasbourg Haute Pierre

Strasbourg, France

CHU Strasbourg

Strasbourg, France

Hopital Foch

Suresnes, France

CH Tourcoing

Tourcoing, France

CH Vannes

Vannes, France

Hôpital Nord-Ouest de Villefranche sur Saone

Villefranche-sur-Saône, France

CHU La Réunion

Saint-Denis, Reunion

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06738771

Related Trials

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

NCT054753667 locations

Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

Conditions

Summary

Eligibility

Plain Language Summary

Locations(48)

Related Trials

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy

Validation of RCC Predicting Model With Emulated-target Trial

Preoperative Serum FGF19 in the Prognosis of Biliary Atresia

Pathobiomes in Gut of Critically Ill Patients